About Us
About Novavax

Novavax has developed a platform upon which we can manufacture a variety of proprietary recombinant nanoparticle vaccines.
Learn More
- About Us
- Board of Directors
- Management Team
- Contact Us
- Careers
Pipeline
Pipeline

Novavax clinical pipeline includes vaccine candidates engineered to elicit differentiated immune responses with potential to provide increased protection.
Learn More
- Clinical Stage Pipeline
  - Clinical Trials
- Presentations
- Partners
- Business Development Contact
Investors
Investors

Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Learn More
- CORPORATE GOVERNANCE
- Investor Presentation
- Analyst Coverage
- Investor Relations Contact
  - Join Our Press Release List
News
News

Novavax has been named a Washington Post Top Workplace for two years running.
Learn More
- Press Releases
- Join Our
  Press Release List
- Novavax in the news
- Contact Us

EVENT DETAILS

EVENT DETAILS

Novavax First Quarter Financial Results

May 8, 2017 from 4:30 PM EDT

Webcast Presentation

Click here for webcast

Title

Novavax First Quarter Financial Results

Date / Time

May 8, 2017 from 4:30 PM EDT

Location

CA

Print Page | Join Our E-mail Alert List